Study Data
hyperkalemia
EVENTS
Baseline data for trial participants were obtained through self-report, medical record review, and questionnaires. In addition to blood for batched analyses collected at baseline and at 36 weeks, pre-HD serum potassium concentration was measured at the following time points: every month; 3–5 days and 2 weeks after each study drug dose increase; and within 1 week after any hyperkalemia events (defined as any serum potassium concentration >6.0 mEq/L, whether obtained for the trial or for clinical purposes). Echocardiography was performed at baseline and at the end of follow-up.